Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide 5 mg vs Semaglutide 1.7 mg Over Three Months: Weight and Appetite

A three-month observational study in 183 adults examined weight and appetite with weekly tirzepatide 5 mg and semaglutide 1.7 mg.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Average weight loss at three monthsSemaglutide 1.7 mg8.15 kgTirzepatide 5 mg11.02 kg

In a three-month study at one clinic in China, adults receiving tirzepatide lost more weight on average than those receiving semaglutide. The comparison included 183 adults with obesity and without diabetes. Physicians chose each person’s treatment, and researchers compared the groups retrospectively [1].

What the doses represent

The study used weekly semaglutide 1.7 mg (86 participants) and weekly tirzepatide 5 mg (97 participants) [1]. In the U.S. weight-management labels, 1.7 mg weekly is a Wegovy maintenance option, with 2.4 mg recommended and Wegovy HD available for some adults who need more weight reduction. The Zepbound label lists 5 mg, 10 mg and 15 mg as weight-management maintenance options [2] [3].

Our guide to doses reached in routine care explains why an available dose can differ from the one people take. This study’s results apply to the two regimens it compared over three months. It cannot establish a dose conversion between the medications.

Weight, appetite and side effects

Average weight loss was 11.02 kg with tirzepatide and 8.15 kg with semaglutide, an unadjusted difference of 2.87 kg (95% confidence interval 1.32–4.41 kg). The authors also estimated that the share reaching the study’s 10% weight-loss threshold was 21.50 percentage points higher with tirzepatide (95% confidence interval 7.45–35.55 points)[1].

The two questionnaires tracked control of eating and appetite. The authors did not report a clear difference between groups in cravings and appetite scores. They also did not detect statistically significant differences in gastrointestinal or psychiatric side effects over three months [1].

How dose affects a price comparison

The dose pricing tool helps compare whether quoted prices change across dose levels. Use the price for the dose you are comparing. This study reports weight and appetite outcomes and does not estimate what either regimen costs.

Frequently asked

Which group lost more weight?
At three months, the tirzepatide group lost 11.02 kg on average and the semaglutide group lost 8.15 kg. The unadjusted difference was 2.87 kg (95% confidence interval 1.32–4.41 kg).
Did the study establish equivalent doses?
The study compared two specific weekly regimens: tirzepatide 5 mg and semaglutide 1.7 mg. It could not establish a conversion between these drugs.
Did either group report more appetite changes?
The study did not detect a clear between-group difference in the food-craving or appetite questionnaire scores. It could not establish that the drugs have equivalent effects on appetite.

Sources

  1. [1] Yao Z, et al. (2026). Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study Diabetes, Metabolic Syndrome and Obesity. PMID 42610030
  2. [2] Novo Nordisk (2026). Wegovy prescribing information, section 2.2 DailyMed, U.S. National Library of Medicine. Source
  3. [3] Eli Lilly (2026). Zepbound prescribing information, recommended maintenance dosage DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence